GlassScriptPhysician profile
Julie A Means
NPI 1982703328
$9,006.58
in general payments reported to CMS, 2019-2025
68 companies · $1,867 in 2025
The $1,867 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,804 · 2020: $686 · 2021: $132 · 2022: $428 · 2023: $1,587 · 2024: $1,503 · 2025: $1,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,860 · Education: $96.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,860.07 |
| Education | $96.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $830.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $620.59 | 2019-2025 | Calquence, Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $619.09 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $525.55 | 2019-2025 | Darzalex, Rybrevant, Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $446.24 | 2019-2025 | Opdivo, Krazati |
| Amgen INC. | $438.74 | 2019-2022 | |
| Celgene Corporation | $388.23 | 2019-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $333.60 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $328.73 | 2019-2025 | |
| Eisai INC. | $322.66 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $278.73 | 2019-2025 | |
| Exelixis INC. | $233.59 | 2019-2024 | Cabometyx |
| Genentech USA, INC. | $218.82 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Gilead Sciences, INC. | $194.56 | 2019-2025 | Trodelvy |
| Incyte Corporation | $184.61 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $183.90 | 2019-2025 | |
| Lilly USA, LLC | $171.68 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $156.44 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Aveo Pharmaceuticals, INC. | $147.20 | 2023-2025 | Fotivda |
| Tersera Therapeutics LLC | $136.63 | 2023-2025 | Zoladex, Xermelo |
| Abbvie INC. | $122.59 | 2020-2025 | |
| Myovant Sciences INC. | $120.05 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.88 | 2019-2024 | Ninlaro, Iclusig, Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $108.83 | 2019-2024 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $107.36 | 2019-2023 | Imbruvica |
| Ipsen Biopharmaceuticals, INC | $103.25 | 2019-2025 | Onivyde |
| Taiho Oncology, INC. | $95.58 | 2019-2025 | |
| Seagen INC. | $81.63 | 2019-2023 | Tukysa |
| Puma Biotechnology, INC. | $80.44 | 2019-2025 | |
| Beone Medicines USA, INC. | $80.17 | 2025 | Tevimbra |
| Genmab U.S., INC. | $73.37 | 2024-2025 | Epkinly |
| Rigel Pharmaceuticals, INC. | $72.39 | 2022-2025 | Rezlidhia, Gavreto, Tavalisse |
| Pharmaessentia USA Corporation | $70.71 | 2024-2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $67.70 | 2019-2024 | Ultomiris |
| Servier Pharmaceuticals LLC | $65.44 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $63.29 | 2019-2025 | |
| Clovis Oncology, INC. | $51.52 | 2019 | |
| G1 Therapeutics, INC. | $46.07 | 2022-2023 | Cosela |
| Dova Pharmaceuticals | $43.86 | 2019-2020 | |
| Astellas Pharma US INC | $42.21 | 2022-2023 | Xospata |
| Mirati Therapeutics, INC. | $41.17 | 2023 | Krazati |
| Emd Serono, INC. | $39.02 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $38.11 | 2024 | Orgovyx |
| Array Biopharma INC | $36.91 | 2019-2024 | Ibrance, Lorbrena, Braftovi |
| Lexicon Pharmaceuticals, INC. | $30.39 | 2019-2020 | |
| Cti Biopharma Corp. | $30.25 | 2023 | Vonjo |
| Tesaro, INC. | $27.09 | 2019 | |
| Foundation Medicine, INC. | $26.76 | 2019 | |
| Shield Therapeutics INC | $23.84 | 2025 | |
| Novocure INC. | $23.11 | 2025 | Optune Lua (Novottf-200t) |
| Nuvation Bio INC. | $23.08 | 2025 | Ibtrozi |
| Aurobindo Pharma USA, INC. | $22.88 | 2020 | |
| Corcept Therapeutics | $21.82 | 2025 | Korlym |
| Kyowa Kirin, INC. | $21.69 | 2025 | |
| Adc Therapeutics America, INC. | $21.68 | 2023 | |
| Sobi, INC | $21.13 | 2024 | |
| Pharmacosmos Therapeutics INC. | $20.65 | 2024 | Cosela |
| Progenics Pharmaceuticals, INC. | $18.82 | 2023 | Pylarify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.63 | 2024 | Gilotrif |
| Kite Pharma, INC. | $18.49 | 2023 | Yescarta |
| Fennec Pharmaceuticals, INC. | $18.28 | 2025 | Fyarro |
| Tolmar Pharmaceuticals, INC. | $17.87 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.58 | 2019 | |
| Beigene USA, INC. | $15.56 | 2023 | Brukinsa |
| Morphosys, US INC. | $15.07 | 2023 | Monjuvi |
| Grifols USA, LLC | $13.86 | 2019 | |
| Mylan Institutional INC. | $11.97 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Means listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.